Publications

ARTICLES

1. Hatton JN, Frone MN, …, Bofill-De Ros X, et al. “Specifications of the ACMG/AMP variant curation guidelines for analysis of germline DICER1 variants”. Human Mutation (2023)

2. Yang A*, Bofill-De Ros X*, Stanton RC, Shi C, et al. “TENT2, TUT4 and TUT7 selectively regulate miRNA sequence and abundance”. Nature Communications (2022)

3. Bofill-De Ros X#, Hong Z, Birkenfeld B, et al. “Flexible pri-miRNA structures enable tunable production of 5’ isomiR”. RNA Biology (2022)

4. Bofill-De Ros X#, Luke B, Guthridge R, et al. “Tumor IsomiR Encyclopedia (TIE): a pan-cancer database of miRNA isoforms”. Bioinformatics (2021)

5. Yang A*, Shao TJ*, Bofill-De Ros X*, Lian C, Villanueva P, Dai L, Gu S. “AGO-bound mature miRNAs are oligouridylated by TUTs and subsequently degraded by DIS3L2”. Nature Communications (2020)

6. Dai L, Hallmark L, Bofill-De Ros X, et al. “Novel, abundant Drosha isoforms are deficient in miRNA processing in cancer cells”. RNA Biology (2020) 

7. Desvignes T, ..., Bofill-De Ros X, et al. “Unification of miRNA and isomiR research: the mirGFF3 format and the mirtop API”. Bioinformatics (2020) 

8. Yang A*, Bofill-De Ros X*, et al. “3’ uridylation Confers miRNAs with novel non-canonical target repertoires”. Molecular Cell (2019)

9. Bofill-De Ros X, et al. “Structural differences between pri-miRNA paralogs promotes alternative Drosha cleavage and expands target repertoires”. Cell Reports (2019) – Cover story

10. Bofill-De Ros X, Chen K, et al. “QuagmiR: A cloud-based application for isomiR big data analytics”. Bioinformatics (2018)

11. Luna J*, Boni J*, Cuatrecasas M, Bofill-De Ros X, et al. “DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth”. Gut (2018)

12. Rodríguez-Comas J, Moreno-Asso A, ..., Bofill-De Ros X, et al. “Stress-induced microRNA-708 impairs β-cell function and growth”. Diabetes (2017).

13. Bofill-De Ros X, Santos M, Vila M, et al. “Genome-wide miR-155 and miR-802 target gene identification in the hippocampus of Ts65Dn Down syndrome mouse model by miRNA sponges”. BMC Genomics (2015).

14. Bofill-De Ros X*, Villanueva E*, Fillat C. “Late-phase miRNA-controlled oncolytic adenovirus for selective killing of cancer cells”. Oncotarget (2015).

15. Bofill-De Ros X, Gironella M., Fillat C., “miR-148a and miR-216a regulated oncolytic adenoviruses targeting pancreatic tumors attenuate tissue damage without perturbation of miRNA activity”. Molecular Therapy (2014).

Reviews and Book Chapters

1. Bofill-De Ros X, Yang A, Gu S. “IsomiRs: Expanding the miRNA repression toolbox beyond the seed”. Biochimica et Biophysica Acta - Gene Regulatory Mechanisms (2019)

2. Bofill-De Ros X, Rovira-Rigau M, Fillat C. “Implications of MicroRNAs in Oncolytic Virotherapy”. Frontiers in Oncology (2017).

3. Bofill-De Ros X, Gu S. “Guidelines for the optimal design of miRNA-based shRNAs”. Methods (2015)

4. Fillat C, Bofill-De Ros X, et al. “Identification of key genes in Down syndrome by gene therapy”. International Medical Review On Down’s Syndrome (2014).

5. Fillat C, José A, Bofill-De Ros X, et al. “Pancreatic cancer gene therapy: From molecular targets to delivery systems”. Cancers (2011)

6. Fillat C, José A, Bofill-De Ros X, et al. “Controlling adenoviral replication to induce oncolytic efficacy”. The Open Gene Therapy Journal (2010)

Commentaries, Editorials AND OTHERS

1. Bofill-De Ros X. "Toward learning the rules that predict siRNA efficacy". Molecular Therapy - Nucleic Acids (2023)

2. Bofill-De Ros X, "Restoration of microRNA metabolism triggers robust antitumor responses". Molecular Therapy - Nucleic Acids (2022)

3. Bofill-De Ros X. "RNA targeting using CasRx can prevent aminoglycoside induced hearing loss". Molecular Therapy - Nucleic Acids (2022)

4. Bofill De Ros X. "Scientists are on a path to sequencing 1 million human genomes and use big data to unlock genetic secrets". The Conversation (2021)

5. Fillat C., Bofill De Ros X. PATENT APPLICATION (2014, PCT 2015).